Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Preferred Dividend Payments (2016 - 2025)

Guided Therapeutics' Preferred Dividend Payments history spans 13 years, with the latest figure at $24000.0 for Q4 2025.

  • On a quarterly basis, Preferred Dividend Payments fell 50.0% to $24000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $148000.0, a 14.94% decrease, with the full-year FY2025 number at $150000.0, down 13.79% from a year prior.
  • Preferred Dividend Payments hit $24000.0 in Q4 2025 for Guided Therapeutics, down from $43000.0 in the prior quarter.
  • Over the last five years, Preferred Dividend Payments for GTHP hit a ceiling of $548000.0 in Q1 2022 and a floor of -$55000.0 in Q1 2021.
  • Historically, Preferred Dividend Payments has averaged $73700.0 across 5 years, with a median of $47500.0 in 2022.
  • Biggest five-year swings in Preferred Dividend Payments: tumbled 558.33% in 2021 and later skyrocketed 1096.36% in 2022.
  • Tracing GTHP's Preferred Dividend Payments over 5 years: stood at $65000.0 in 2021, then fell by 23.08% to $50000.0 in 2022, then decreased by 2.0% to $49000.0 in 2023, then decreased by 2.04% to $48000.0 in 2024, then crashed by 50.0% to $24000.0 in 2025.
  • Business Quant data shows Preferred Dividend Payments for GTHP at $24000.0 in Q4 2025, $43000.0 in Q3 2025, and $45000.0 in Q2 2025.